Paul Hamlin

15PUBLICATIONS
75CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 10, 2026
Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Feb 08, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye

|Sep 20, 2024
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.

Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin

|Jan 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP.

Kurt S Bantilan, Alexandra N Smith, Matthew J Maurer

|Jun 12, 2023
Retrospective characterization of nodal marginal zone lymphoma.

Robert Stuver, Esther Drill, David Qualls

Pageof 3

Frequent Collaborators

9 joint publications

Gilles Salles

8 joint publications

Andrew D Zelenetz

6 joint publications

Ariela Noy

5 joint publications

Matthew Matasar